Neuberger Berman Group LLC increased its position in shares of Merck & Co. (NYSE:MRK) by 0.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,490,698 shares of the company’s stock after buying an additional 3,775 shares during the period. Neuberger Berman Group LLC owned about 0.05% of Merck & Co. worth $85,879,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Accredited Investors Inc. raised its stake in shares of Merck & Co. by 0.3% in the first quarter. Accredited Investors Inc. now owns 9,125 shares of the company’s stock worth $483,000 after buying an additional 23 shares in the last quarter. Thomaspartners Inc. raised its stake in shares of Merck & Co. by 0.3% in the first quarter. Thomaspartners Inc. now owns 9,024 shares of the company’s stock worth $477,000 after buying an additional 26 shares in the last quarter. Vicus Capital raised its stake in shares of Merck & Co. by 0.3% in the first quarter. Vicus Capital now owns 11,121 shares of the company’s stock worth $588,000 after buying an additional 37 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management raised its stake in shares of Merck & Co. by 0.8% in the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 4,738 shares of the company’s stock worth $250,000 after buying an additional 39 shares in the last quarter. Finally, NorthRock Partners LLC raised its stake in shares of Merck & Co. by 1.2% in the first quarter. NorthRock Partners LLC now owns 3,862 shares of the company’s stock worth $206,000 after buying an additional 45 shares in the last quarter. 72.93% of the stock is owned by hedge funds and other institutional investors.
Merck & Co. (NYSE:MRK) traded down 0.13% during midday trading on Monday, reaching $62.33. The company’s stock had a trading volume of 3,935,135 shares. The stock’s 50 day moving average is $62.76 and its 200 day moving average is $58.03. Merck & Co. has a 12-month low of $47.97 and a 12-month high of $64.00. The stock has a market cap of $172.36 billion, a P/E ratio of 34.19 and a beta of 0.68.
Merck & Co. (NYSE:MRK) last posted its earnings results on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.02. The firm earned $9.84 billion during the quarter, compared to analysts’ expectations of $9.79 billion. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 earnings per share. Analysts anticipate that Merck & Co. will post $3.75 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be paid a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a yield of 2.95%. The ex-dividend date is Tuesday, September 13th. Merck & Co.’s payout ratio is 101.10%.
A number of analysts recently weighed in on MRK shares. Goldman Sachs Group Inc. reaffirmed a “neutral” rating and issued a $60.00 price objective on shares of Merck & Co. in a research note on Wednesday, June 8th. Argus reaffirmed a “buy” rating on shares of Merck & Co. in a research note on Thursday, June 9th. Jefferies Group lowered their price objective on shares of Merck & Co. from $54.00 to $53.00 and set a “hold” rating for the company in a research note on Tuesday, June 14th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price objective on shares of Merck & Co. in a research note on Tuesday, June 28th. Finally, Vetr raised shares of Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 price objective for the company in a research note on Monday, July 4th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of €63.20 ($70.23).
In related news, EVP Adam H. Schechter sold 39,200 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total transaction of €2,454,312.00 ($2,727,013.33). Following the completion of the sale, the executive vice president now owns 39,200 shares in the company, valued at €2,454,312 ($2,727,013.33). The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kenneth C. Frazier sold 60,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of €58.00 ($64.44), for a total value of €3,480,000.00 ($3,866,666.67). Following the sale, the chief executive officer now owns 554,856 shares of the company’s stock, valued at approximately €32,181,648 ($35,757,386.67). The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.